Search Results
Sep 03, 2026, 07:00 ET Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
LOS ANGELES, Sept. 3, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage
More news about: Armata Pharmaceuticals, Inc.
Aug 12, 2026, 16:05 ET Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
LOS ANGELES, Aug. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage
More news about: Armata Pharmaceuticals, Inc.
Jul 20, 2026, 07:00 ET Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
LOS ANGELES, July 20, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage
More news about: Armata Pharmaceuticals, Inc.
Jul 13, 2026, 07:00 ET Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
LOS ANGELES, July 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage
More news about: Armata Pharmaceuticals, Inc.
Jul 13, 2026, 05:39 ET Cathay United Bank chi nhánh Thành phố Hồ Chí Minh nhận ba giải thưởng HR Asia về Nơi làm việc tốt nhất Châu Á, Dẫn đầu công nghệ và Chuyển đổi nguồn nhân lực xuất sắc
bản, bao gồm Chương trình Cathay Management Associate (CMA), Chương trình International Master (IMP) và Chương trình Associate Relationship Manager (ARMP). Các chương trình này mang đến cho nhân viên cơ hội được đào tạo, kinh nghiệm làm việc quốc tế và trải nghiệm luân chuyển công tác, qua đó nâng cao
More news about: Cathay United Bank
Jun 23, 2026, 07:00 ET Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02
LOS ANGELES, June 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage
More news about: Armata Pharmaceuticals, Inc.
May 13, 2026, 16:30 ET Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
LOS ANGELES, May 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage
More news about: Armata Pharmaceuticals, Inc.
May 07, 2026, 07:00 ET Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
LOS ANGELES, May 7, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage
More news about: Armata Pharmaceuticals, Inc.
May 04, 2026, 07:00 ET Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
LOS ANGELES, May 4, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage
More news about: Armata Pharmaceuticals, Inc.
Apr 27, 2026, 07:00 ET Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors
LOS ANGELES, April 27, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage
More news about: Armata Pharmaceuticals, Inc.
Mar 25, 2026, 16:05 ET Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
LOS ANGELES, March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage
More news about: Armata Pharmaceuticals, Inc.
Mar 19, 2026, 07:00 ET Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
LOS ANGELES, March 19, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage
More news about: Armata Pharmaceuticals, Inc.
Feb 23, 2026, 07:00 ET Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage
More news about: Armata Pharmaceuticals, Inc.
Jan 13, 2026, 07:42 ET Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated Staphylococcus aureus Bacteremia
LOS ANGELES, Jan. 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage
More news about: Armata Pharmaceuticals, Inc.
Nov 18, 2025, 07:00 ET Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
LOS ANGELES, Nov. 18, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics
More news about: Armata Pharmaceuticals, Inc.
Nov 12, 2025, 16:05 ET Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
LOS ANGELES, Nov. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics
More news about: Armata Pharmaceuticals, Inc.
Nov 10, 2025, 07:00 ET Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
LOS ANGELES, Nov. 10, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics
More news about: Armata Pharmaceuticals, Inc.
Oct 22, 2025, 11:10 ET Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™
LOS ANGELES, Oct. 22, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics
More news about: Armata Pharmaceuticals, Inc.
Oct 14, 2025, 07:00 ET Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™
LOS ANGELES, Oct. 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics
More news about: Armata Pharmaceuticals, Inc.